News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups
Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups
Hosted by Robert Michel
Sign In

Winners of the Qualcomm Tricorder XPRIZE for Medical Laboratory Testing Were Announced in April, Five Years After the Competition Began

Jul 24, 2017 | Laboratory Pathology

More than 312 teams applied for the completion and the prize-winning hand-held device uses clinical laboratory assays to diagnose up to 34 different medical conditions

Star Trek fans among clinical laboratory manager and pathologist will be excited to learn that the winners of the Qualcomm Tricorder XPRIZE were announced earlier this year, five years after the contest began. The purpose of the XPRIZE competition was to challenge teams to create a mobile integrated diagnostic device that weighed less than five pounds and had the ability to monitor health metrics and diagnose 13 specific health conditions. The premise for the contest was inspired by the Star Trek medical tricorder that was first conceptualized on the television show “Star Trek” in the 1960s.

In the popular science-fiction show, the tricorder was a multifunctional hand-held device used for sensor scanning, data analysis, and recording data. The name “tricorder” was an abbreviation for the full name of the gadget, “tri-function recorder,” which referred to the three primary functions of the device.

Based in Culver City, Calif, the XPRIZE Foundation is a non-profit organization that creates and oversees prestigious technological competitions for the purpose of prompting innovations that could benefit humanity.

Handheld Device That Can Perform Multiple Clinical Laboratory Assays

The Qualcomm Tricorder XPRIZE competition was launched in January 2012. Participants had until August 2013 to register for the contest. The qualifying round was held the following August. Three hundred and twelve teams entered the competition. Qualifiers had until March 2015 to design and build their prototypes. Consumer testing on the products began in September 2016 and the winners were announced in April 2017.

The top prize of $2.6 million was awarded to Final Frontier Medical Devices, the team led by Basil Harris, MD, an emergency room physician with a PhD in Materials Engineering led the team, along with his network engineer brother, George Harris.

Basil Leaf Technologies, founded by Basil Harris, MD, PhD, FACEP (above center); and his brother George, a Network Engineer (second from left), is a medical technology company headquartered in Paoli, Pa. Their winning entry, called DxtER (pronounced Dexter), is a small FDA-approved group of medical devices that enable consumers to diagnose illnesses at home or remotely and share that data with healthcare providers. (Photo copyright: XPRIZE Foundation.)

The collection of FDA-approved devices that make up the “tricorder” includes sensors designed to gather data about vital signs, body chemistry, and biological functions. The DxtER device walks patients through the self-diagnosis of 34 medical conditions. The instruments include:

·       A compact spirometer that calculates lung strength;

·       A test kit for Mononucleosis;

·       A heart rate monitor;

·       A respiration monitor;

·       The DxtER Orb, a digital stethoscope that also serves as a thermometer; and

·       An artificial intelligence (AI) “engine” that diagnoses medical conditions.

DxtER communicates with a tablet and/or smartphone-based app. Since the components are FDA-approved, diagnostic test results can be taken directly to healthcare professionals.

“You can [receive the] results and take them to the ER or to your physician or whoever’s helping you, and they can build off those results,” George Harris explained in an Engadget article. “They don’t have to start back at square one. They can jump off at that point and move on with their healthcare.”

Basil Leaf Technologies’ DxtER “tricorder” (above) enables the user to self-diagnose up to 34 medical conditions. Each individual component is FDA-approved, so hospital physicians can rely on the accuracy of the test results. (Photo copyright: XPRIZE Foundation.)

According to the contest website, “at the heart of DxtER is an artificially intelligent engine that learned to diagnose by integrating years of experience in clinical emergency medicine with data analysis from actual patients having a variety of medical conditions and outcomes.”

“It is very exciting that our vision of mobile, personalized patient-centric healthcare is getting closer to becoming a reality thanks to the great work of the Qualcomm Tricorder XPRIZE teams,” declared Paul E. Jacobs, PhD, Executive Chairman of Qualcomm Incorporated (NASDAQ:QCOM) in an XPRIZE press release. “Creating technology breakthroughs in an industry as complex as healthcare is quite a milestone, and what these teams accomplished is a great stepping stone to making mobile healthcare a viable option across the world.”

DxtER Functions Like a Mobile Medical Laboratory

In addition to the $2.6-million prize, Qualcomm Foundation is giving the Basil Leaf team $3.8 million to further develop the device. This amount includes a:

·       $2.5 million proposal grant to the University of California San Diego; and a

·       $1.6-million gift from the Roddenberry Foundation to adapt the tricorder for hospital use in the developing world.

The XPRIZE competition required contestants to create a tricorder device that could accurately diagnose 13 health conditions. This included 10 core conditions and a choice of three elective health conditions. The devices also needed to be able to acquire five real-time vital signs:

1.     Blood pressure;

2.     Heart rate;

3.     Oxygen saturation;

4.     Respiratory rate; and

5.     Temperature.

The 10 core conditions the devices had to be able to identify were:

1.     Anemia;

2.     Atrial Fibrillation;

3.     Chronic Obstructive Pulmonary Disease;

4.     Diabetes Mellitus;

5.     Leukocytosis;

6.     Pneumonia;

7.     Otitis;

8.     Sleep Apnea;

9.     Urinary Tract Infection; and

10.  Absence of condition.

The contest also required participants to choose three elective conditions from the following list:

·       Cholesterol screen;

·       Food-borne illness;

·       Human Immunodeficiency Virus (HIV) screen;

·       Hypertension;

·       Hypothyroidism/Hyperthyroidism;

·       Melanoma;

·       Mononucleosis;

·       Pertussis;

·       Shingles, and

·       Strep throat.

It is notable that the TriCorder XPRIZE—with its $2.6 million prize—generated entries from 312 teams. Pathologists and clinical laboratory managers can take this high number of entrants as a sign that the ongoing advances in technology are poised to support a new generation of very small medical lab testing devices. Thus, miniaturized diagnostic technologies, when combined with more sophisticated computing chips and software are making it simpler and more feasible to pack multiple diagnostic instruments into a hand-held package.

—JP Schlingman

Related Information:

Final Frontier Medical Devices

Family-led Team Takes Top Prize in Qualcomm Tricorder XPRIZE Competition for Consumer Medical Device Inspired by Star Trek

The Contest to Build the First Star Trek Tricorder Has a Winner [Infographic]

XPRIZE Winner Says its Tricorder is Better Than ‘Star Trek’

Underdog Team Wins Millions in Competition to Make Real-Life Tricorder

Star Trek’s “Tricorder” Medical Scanner Just Got Closer to Becoming a Reality

Qualcomm Tricorder XPRIZE Goes to US Team for Device Fusing AI, IoT, Health

Tricorder X Prize – Wikipedia

Star Trek’s Tricorder, Realized? This Device Uses AI to Diagnose Medical Conditions

The Race to Build a Real Star Trek Tricorder

Qualcomm TriCorder XPRIZE Selects 10 Finalists: Next Step Is for Devices to Diagnose Patients using Clinical Laboratory Test Technologies and Similar Diagnostic Tools

Consumers Increasingly Purchase Medical Laboratory Self-Test Kits for Blood Glucose, Cholesterol, and Colon Cancer Screening, according to Consumer Reports

Jan 20, 2017 | Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Testing, Management & Operations

The self-monitoring/self-test market is expected to swell to $19 billion by 2019, offering opportunities for pathologists and clinical laboratories to advise patients and ensure the proper use of home tests

Might the future of clinical laboratory tests be sitting on the shelf at your corner pharmacy right now? Patient self-testing and screening kits continue to garner the approvals of Consumer Reports’ medical advisors.

That’s happening because the Food and Drug Administration (FDA) continues to clear many do-it-yourself tests that traditionally were performed in medical laboratories by qualified personnel, much to the chagrin of some doctors.

Empowered healthcare consumers are checking their cholesterol, monitoring their diabetes, and more, using health screening kits that range from $8 to $175, according to a Consumer Reports on Health article, which advised consumers to use self-tests judiciously and share the results with their physicians. (more…)

Australian Teens Working in Their High School Laboratory Successfully Replicate the Primary Chemical Components of the Costly Drug Daraprim

Jan 13, 2017 | Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Testing

Improvements in technology are enabling individuals with basic clinical laboratory knowledge to reproduce expensive medical products using low-cost, less complicated methods

Advances in technology made it possible for a group of high school students in Australia to successfully replicate the primary ingredients of a pharmaceutical drug called Pyrimethamine, which is sold under the name Daraprim. It is another demonstration of how today’s sophisticated technologies can be harnessed by individuals with minimal scientific training to produce complex products.

In recent years, Dark Daily has chronicled the successes of high school students in the United States who did the following: (more…)

UK Research Team Develops Diagnostic USB Device That Detects HIV and Measures Viral Load from Human Blood for Use in Developing Countries

Jan 6, 2017 | Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology

Clinical laboratory assays on a USB stick could become a powerful tool in the treatment and containment of HIV-1 in low-resource regions, such as sub-Saharan Africa

Imagine a small USB device that plugs into a computer and, using a small sample of blood, is capable of detecting the presence of HIV and measuring its viral load in that individual. Such technology exists and was created by a team of scientists in the United Kingdom (UK).  However, it is not yet ready for use by clinical laboratories.

Researchers at Imperial College London company, DNA Electronics, have developed a diagnostic USB stick that measures the presence of human immunodeficiency virus (HIV), as well as the viral load in a person’s blood, and in less than 30 minutes. The platform promises to be an important milestone for the medical laboratory treatment and containment of pandemic diseases that pose a serious threat to global health.

A story published on the mobile technology news blog Quartz pointed out that more than 24-million of the 37-million people worldwide infected with HIV live in sub-Saharan Africa. It is widely recognized that high cost and lack of access to medical care and clinical laboratory services remain a barrier to diagnosis, treatment, and containment of the disease. “[I]mproving diagnostics is now a key part of global strategies to combat [HIV],” wrote the study authors in a paper published in Nature Research journal Scientific Reports. (more…)

Paper Microfluidic Devices Offer New Potential for Affordable Point-of-Care Tests for Use in Developing Countries That Have Few Clinical Laboratories

Jul 29, 2016 | Instruments & Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Laboratory Testing

Paper-based devices could perform complex, multistep diagnostic tests at a fraction of the cost of traditional medical laboratory analysis

Many research teams are racing to create paper-based devices for medical laboratory tests. Their primary goal is develop a cheap, fast, reliable way to perform diagnostic testing in third world settings, where modern clinical laboratories are few and far between. One development team is working to combine lab-on-a-chip technologies with the low cost of paper-based platforms.

Meanwhile, over the past decade, point-of-care testing (POCT) has revolutionized diagnosis and treatment options for a myriad of conditions. In developing regions or remote areas, low-cost POCT improves accessibility to vital tests for infectious diseases, such as HIV, Malaria, and Ebola, as well as acute medical conditions, such as sepsis.

In the past eight years, Dark Daily has reported many times on the emergence of new POCT devices. From lactic acid screening to the lab-in-a-needle, which is used for detecting liver toxicity, the ability to produce a quick and accurate diagnosis without intensive clinical laboratory testing is growing.

However, one area where many POCT devices face challenges is in surviving extended environmental exposure. This does not pose an issue in major research hospitals or health systems. However, the consequences can be severe when considering the often harsh, resource-limited conditions of developing countries—one area in which POCT stands to offer the greatest value. (more…)

;